Vridapa-M 5/500 Tablet ER

Overview Vridapa-M 5/500 Tablet ER

Diabeta-Duo 5/500 Extended-Release tablets combine two medications to manage type 2 diabetes. This treatment helps regulate elevated blood glucose, lessening the likelihood of severe diabetic complications, including heart disease. Diabeta-Duo 5/500 ER can be taken with food, consistently at the same time each day to aid adherence. Dosage is determined by your physician; cessation requires their consultation, as abrupt discontinuation may elevate blood sugar, risking serious consequences such as kidney impairment and vision loss. This medication forms part of a comprehensive diabetes management plan incorporating diet, exercise, and weight control as directed by your doctor. Common side effects include throat irritation, nasal stuffiness, rhinorrhea, headache, nausea, vomiting, and diarrhea. Adequate hydration mitigates dehydration. Genital fungal infections are a potential side effect; good hygiene can reduce this risk. Prior to commencing treatment, disclose any kidney or liver issues, urinary tract infections, or diuretic use to your doctor. Pregnant or lactating individuals must consult their physician. Limit alcohol consumption, as it may exacerbate side effects. Regular blood glucose monitoring is essential during treatment.

Primary Ingredients of Vridapa-M 5/500 Tablet ER

No text provided to rephrase.

Uses of Vridapa-M 5/500 Tablet ER

Managing Type 2 Diabetes

Major Benefits of Vridapa-M 5/500 Tablet ER:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment period. Ingest the entire tablet without chewing, crushing, or fracturing it. Vridapa-M 5/500 Extended-Release Tablet should be administered with a meal.

Common Side effects of Vridapa-M 5/500 Tablet ER:

• Nausea
• Vomiting
• Diarrhea
• Genital fungal infection
• Nasopharyngitis (inflammation of the throat and nasal passages)
• Urinary tract infection
• Polyuria
• Flatulence
• Skin rash
• Taste change
• Difficulty in urination
• Hypoglycemia (low blood glucose level)
• Tremors
• Dizziness
• Back pain
• Increased hematocrit
• Decreased creatinine clearance
• Dyslipidemia

How to use Vridapa-M 5/500 Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Vridapa-M 5/500 Tablet ER whole; avoid chewing, crushing, or breaking it. Administer this extended-release tablet with a meal.

How Vridapa-M 5/500 Tablet ER works:

Vridapa-M 5/500 Extended-Release tablets combine dapagliflozin and metformin to effectively manage blood glucose. Dapagliflozin facilitates glucose excretion via the urine, while metformin reduces hepatic glucose production, slows intestinal glucose uptake, and enhances insulin responsiveness. This dual action optimizes blood sugar regulation.

What if you forget to take Vridapa-M 5/500 Tablet ER :

Should you forget a Vridapa-M 5/500 Tablet ER dose, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing pattern. Avoid taking a double dose.